Recent Updates
Recently added Catalysts
Drug Modality Leaderboard
Top biotechs by clinical-trial depth in each drug modality. Counts include all upcoming trials (completion date ≥ 2026-02) from ClinicalTrials.gov.
Monoclonal antibody
3,017 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 |  AZNAstraZeneca PLC | 316 | 130 | $261.2B |
| 2 |  MRKMerck & Company, Inc. | 315 | 81 | $369.8B |
| 3 | R RHHBYRoche Holding AG | 217 | 66 | — |
| 4 |  JNJJohnson & Johnson | 193 | 59 | $621.2B |
| 5 |  BMYBristol-Myers Squibb Company | 173 | 33 | $124.9B |
| 6 |  REGNRegeneron Pharmaceuticals, Inc. | 138 | 31 | $82.9B |
| 7 |  ABBVAbbVie Inc. | 128 | 32 | $503.2B |
| 8 |  NVSNovartis AG | 122 | 36 | $313.2B |
| 9 |  SNYSanofi | 108 | 24 | $99.0B |
| 10 |  GSKGSK plc | 108 | 33 | $101.2B |
Small molecule
1,928 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | AZNAstraZeneca PLC | 167 | 52 | $261.2B |
| 2 | NVSNovartis AG | 142 | 37 | $313.2B |
| 3 | MRKMerck & Company, Inc. | 133 | 35 | $369.8B |
| 4 | ABBVAbbVie Inc. | 119 | 40 | $503.2B |
| 5 | BMYBristol-Myers Squibb Company | 103 | 29 | $124.9B |
| 6 |  PFEPfizer, Inc. | 98 | 26 | $170.1B |
| 7 |  LLYEli Lilly and Company | 75 | 22 | $1.2T |
| 8 | JNJJohnson & Johnson | 73 | 24 | $621.2B |
| 9 |  INCYIncyte Corporation | 71 | 14 | $23.0B |
| 10 | R RHHBYRoche Holding AG | 69 | 21 | — |
Bispecific
543 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | JNJJohnson & Johnson | 82 | 19 | $621.2B |
| 2 | R RHHBYRoche Holding AG | 64 | 11 | — |
| 3 | AZNAstraZeneca PLC | 54 | 20 | $261.2B |
| 4 | REGNRegeneron Pharmaceuticals, Inc. | 40 | 8 | $82.9B |
| 5 |  AMGNAmgen Inc. | 39 | 12 | $237.0B |
| 6 |  GMABGenmab A/S | 35 | 7 | $24.7B |
| 7 | PFEPfizer, Inc. | 29 | 10 | $170.1B |
| 8 | BMYBristol-Myers Squibb Company | 24 | 4 | $124.9B |
| 9 | ABBVAbbVie Inc. | 20 | 3 | $503.2B |
| 10 | SNYSanofi | 17 | 4 | $99.0B |
ADC
496 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | MRKMerck & Company, Inc. | 98 | 32 | $369.8B |
| 2 | AZNAstraZeneca PLC | 80 | 33 | $261.2B |
| 3 |  GILDGilead Sciences, Inc. | 49 | 12 | $190.4B |
| 4 | GSKGSK plc | 46 | 15 | $101.2B |
| 5 | PFEPfizer, Inc. | 37 | 9 | $170.1B |
| 6 | ABBVAbbVie Inc. | 36 | 6 | $503.2B |
| 7 | R RHHBYRoche Holding AG | 23 | 5 | — |
| 8 |  ADCTADC Therapeutics SA | 13 | 1 | $192M |
| 9 |  BNTXBioNTech SE | 10 | 3 | $23.1B |
| 10 |  ONCBeOne Medicines Ltd. | 9 | — | $42.4B |
Vaccine
341 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | SNYSanofi | 54 | 12 | $99.0B |
| 2 | PFEPfizer, Inc. | 48 | 18 | $170.1B |
| 3 | GSKGSK plc | 42 | 15 | $101.2B |
| 4 | S SVASinovac Biotech, Ltd | 35 | 17 | $465M |
| 5 | MRKMerck & Company, Inc. | 29 | 8 | $369.8B |
| 6 |  MRNAModerna, Inc. | 28 | 4 | $98.1B |
| 7 | BNTXBioNTech SE | 19 | 5 | $23.1B |
| 8 |  VALNValneva SE | 8 | 2 | $528M |
| 9 | BMYBristol-Myers Squibb Company | 7 | — | $124.9B |
| 10 |  TAKTakeda Pharmaceutical Company Limited | 6 | 3 | $63.9B |
Recombinant protein
270 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | R RHHBYRoche Holding AG | 35 | 9 | — |
| 2 | MRKMerck & Company, Inc. | 14 | 5 | $369.8B |
| 3 |  IOVAIovance Biotherapeutics, Inc. | 13 | 1 | $6.6B |
| 4 | AZNAstraZeneca PLC | 12 | 1 | $261.2B |
| 5 |  IBRXImmunityBio, Inc. | 12 | 1 | $9.2B |
| 6 | SNYSanofi | 12 | 4 | $99.0B |
| 7 | JNJJohnson & Johnson | 12 | 5 | $621.2B |
| 8 | PFEPfizer, Inc. | 11 | 6 | $170.1B |
| 9 |  BMRNBioMarin Pharmaceutical Inc. | 10 | 3 | $10.7B |
| 10 | NVSNovartis AG | 9 | 3 | $313.2B |
CAR-T
247 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | BMYBristol-Myers Squibb Company | 34 | 5 | $124.9B |
| 2 | NVSNovartis AG | 26 | 4 | $313.2B |
| 3 | GILDGilead Sciences, Inc. | 22 | 5 | $190.4B |
| 4 | AZNAstraZeneca PLC | 19 | 3 | $261.2B |
| 5 | IOVAIovance Biotherapeutics, Inc. | 12 | 1 | $6.6B |
| 6 |  KYTXKyverna Therapeutics, Inc. | 11 | — | $361M |
| 7 | JNJJohnson & Johnson | 10 | 2 | $621.2B |
| 8 |  FATEFate Therapeutics, Inc. | 6 | — | $248M |
| 9 |  AUTLAutolus Therapeutics plc | 6 | — | $431M |
| 10 |  CRSPCRISPR Therapeutics AG | 6 | — | $4.9B |
Gene therapy
222 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | NVSNovartis AG | 16 | 5 | $313.2B |
| 2 | MRKMerck & Company, Inc. | 12 | 5 | $369.8B |
| 3 | CRSPCRISPR Therapeutics AG | 9 | — | $4.9B |
| 4 | R RHHBYRoche Holding AG | 8 | 2 | — |
| 5 |  SRPTSarepta Therapeutics, Inc. | 8 | 3 | $2.0B |
| 6 |  RAREUltragenyx Pharmaceutical Inc. | 7 | 3 | $1.6B |
| 7 | ABBVAbbVie Inc. | 7 | 2 | $503.2B |
| 8 |  ADVMAdverum Biotechnologies, Inc. | 6 | 2 | $96M |
| 9 |  FDMT4D Molecular Therapeutics, Inc. | 6 | — | $697M |
| 10 | E ELVElevance Health, Inc. | 6 | — | $94.1B |
Radioconjugate
193 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | NVSNovartis AG | 55 | 6 | $313.2B |
| 2 |  LNTHLantheus Holdings, Inc. | 14 | 2 | $6.5B |
| 3 |  TLXTelix Pharmaceuticals Limited | 12 | 6 | $3.4B |
| 4 | B BAYRYBayer AG | 12 | 1 | — |
| 5 | AZNAstraZeneca PLC | 9 | 2 | $261.2B |
| 6 | LLYEli Lilly and Company | 8 | 1 | $1.2T |
| 7 |  GEHCGE HealthCare Technologies Inc. | 7 | — | $31.2B |
| 8 | BMYBristol-Myers Squibb Company | 6 | 1 | $124.9B |
| 9 |  YMABY-mAbs Therapeutics, Inc. | 6 | — | $391M |
| 10 |  EXELExelixis, Inc. | 5 | — | $16.0B |
Peptide
169 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 |  NVONovo Nordisk A/S | 76 | 26 | $174.4B |
| 2 | LLYEli Lilly and Company | 71 | 46 | $1.2T |
| 3 | REGNRegeneron Pharmaceuticals, Inc. | 2 | — | $82.9B |
| 4 | R RHHBYRoche Holding AG | 2 | — | — |
| 5 | SNYSanofi | 2 | — | $99.0B |
| 6 | AZNAstraZeneca PLC | 2 | 1 | $261.2B |
| 7 |  GTBPGT Biopharma, Inc. | 1 | — | $10M |
| 8 |  VANIVivani Medical, Inc. | 1 | — | $105M |
| 9 |  GUTSFractyl Health, Inc. | 1 | — | $15M |
| 10 |  IRTCiRhythm Holdings, Inc. | 1 | — | $3.7B |
Oligonucleotide
145 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | NVSNovartis AG | 37 | 17 | $313.2B |
| 2 |  ALNYAlnylam Pharmaceuticals, Inc. | 17 | 4 | $30.1B |
| 3 |  BIIBBiogen Inc. | 16 | 6 | $35.6B |
| 4 |  IONSIonis Pharmaceuticals, Inc. | 14 | 12 | $7.4B |
| 5 | AZNAstraZeneca PLC | 8 | 1 | $261.2B |
| 6 | GSKGSK plc | 7 | 2 | $101.2B |
| 7 | REGNRegeneron Pharmaceuticals, Inc. | 6 | — | $82.9B |
| 8 |  WVEWave Life Sciences Ltd. | 4 | — | $664M |
| 9 | RAREUltragenyx Pharmaceutical Inc. | 3 | 2 | $1.6B |
| 10 |  TRDAEntrada Therapeutics, Inc. | 3 | — | $181M |
mRNA
106 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | MRNAModerna, Inc. | 44 | 4 | $98.1B |
| 2 | SNYSanofi | 9 | — | $99.0B |
| 3 | BNTXBioNTech SE | 7 | 2 | $23.1B |
| 4 | PFEPfizer, Inc. | 6 | — | $170.1B |
| 5 | GSKGSK plc | 6 | 2 | $101.2B |
| 6 | MRKMerck & Company, Inc. | 5 | 2 | $369.8B |
| 7 |  BEAMBeam Therapeutics Inc. | 2 | — | $2.6B |
| 8 |  GNPXGenprex, Inc. | 2 | — | $2M |
| 9 |  RNACCartesian Therapeutics, Inc. | 2 | 1 | $194M |
| 10 | CRSPCRISPR Therapeutics AG | 2 | — | $4.9B |
Cell therapy
101 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | IOVAIovance Biotherapeutics, Inc. | 12 | 1 | $6.6B |
| 2 | JNJJohnson & Johnson | 10 | 7 | $621.2B |
| 3 | TAKTakeda Pharmaceutical Company Limited | 6 | 2 | $63.9B |
| 4 | PFEPfizer, Inc. | 6 | 3 | $170.1B |
| 5 | BMYBristol-Myers Squibb Company | 5 | 1 | $124.9B |
| 6 | SNYSanofi | 4 | — | $99.0B |
| 7 | INCYIncyte Corporation | 4 | — | $23.0B |
| 8 | GSKGSK plc | 4 | — | $101.2B |
| 9 | IBRXImmunityBio, Inc. | 3 | — | $9.2B |
| 10 | AZNAstraZeneca PLC | 3 | 2 | $261.2B |
Enzyme replacement
43 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | SNYSanofi | 15 | 3 | $99.0B |
| 2 | BMRNBioMarin Pharmaceutical Inc. | 7 | 1 | $10.7B |
| 3 | AZNAstraZeneca PLC | 5 | 3 | $261.2B |
| 4 |  FOLDAmicus Therapeutics, Inc. | 4 | 2 | $4.5B |
| 5 | TAKTakeda Pharmaceutical Company Limited | 4 | — | $63.9B |
| 6 | I ICLRIcon Plc | 3 | — | $14.1B |
| 7 |  DNLIDenali Therapeutics Inc. | 2 | — | $3.0B |
| 8 |  GRCEGrace Therapeutics, Inc. | 1 | 1 | $41M |
| 9 | RAREUltragenyx Pharmaceutical Inc. | 1 | — | $1.6B |
| 10 | ABBVAbbVie Inc. | 1 | — | $503.2B |
Gene editing
37 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | CRSPCRISPR Therapeutics AG | 9 | — | $4.9B |
| 2 |  NTLAIntellia Therapeutics, Inc. | 5 | 3 | $1.6B |
| 3 |  PRMEPrime Medicine, Inc. | 4 | — | $691M |
| 4 |  VERVVerve Therapeutics, Inc. | 4 | — | $992M |
| 5 |  DTILPrecision BioSciences, Inc. | 3 | — | $185M |
| 6 |  VRTXVertex Pharmaceuticals Incorporated | 3 | 3 | $133.1B |
| 7 |  CRBUCaribou Biosciences, Inc. | 3 | — | $58M |
| 8 | BEAMBeam Therapeutics Inc. | 2 | — | $2.6B |
| 9 |  SGMOSangamo Therapeutics, Inc. | 1 | — | $74M |
| 10 | REGNRegeneron Pharmaceuticals, Inc. | 1 | — | $82.9B |
Cancer vaccine
35 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | BMYBristol-Myers Squibb Company | 5 | — | $124.9B |
| 2 | MRKMerck & Company, Inc. | 4 | — | $369.8B |
| 3 | BNTXBioNTech SE | 3 | — | $23.1B |
| 4 | R RHHBYRoche Holding AG | 2 | — | — |
| 5 |  CADLCandel Therapeutics, Inc. | 2 | 1 | $640M |
| 6 | REGNRegeneron Pharmaceuticals, Inc. | 2 | — | $82.9B |
| 7 | PFEPfizer, Inc. | 1 | — | $170.1B |
| 8 |  GOVXGeoVax Labs, Inc. | 1 | — | $2M |
| 9 |  TMOThermo Fisher Scientific Inc | 1 | 1 | $254.2B |
| 10 | INCYIncyte Corporation | 1 | — | $23.0B |
PROTAC
32 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | PFEPfizer, Inc. | 7 | 2 | $170.1B |
| 2 |  KYMRKymera Therapeutics, Inc. | 5 | — | $9.4B |
| 3 | ONCBeOne Medicines Ltd. | 4 | 2 | $42.4B |
| 4 |  ARVNArvinas, Inc. | 4 | — | $487M |
| 5 |  NRIXNurix Therapeutics, Inc. | 3 | — | $2.7B |
| 6 |  GLUEMonte Rosa Therapeutics, Inc. | 2 | — | $957M |
| 7 |  CCCCC4 Therapeutics, Inc. | 2 | — | $390M |
| 8 | NVSNovartis AG | 2 | — | $313.2B |
| 9 |  DCOYDecoy Therapeutics Inc. | 1 | — | $701048 |
| 10 | BMYBristol-Myers Squibb Company | 1 | 1 | $124.9B |
Oncolytic virus
27 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 |  REPLReplimune Group, Inc. | 10 | 1 | $1.1B |
| 2 | AMGNAmgen Inc. | 3 | — | $237.0B |
| 3 | O ONCYOncolytics Biotech Inc. | 2 | — | $65M |
| 4 |  GNLXGenelux Corporation | 2 | 1 | $94M |
| 5 |  CGONCG Oncology, Inc. | 2 | 2 | $5.5B |
| 6 |  JAZZJazz Pharmaceuticals plc | 1 | — | $13.8B |
| 7 |  AGENAgenus Inc. | 1 | — | $289M |
| 8 | CADLCandel Therapeutics, Inc. | 1 | — | $640M |
| 9 |  TOVXTheriva Biologics, Inc. | 1 | — | $9M |
| 10 |  IQVIQVIA Holdings, Inc. | 1 | — | $45.5B |
Nanomedicine
14 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | C CNSYCerenome, Inc. Common Stock | 4 | — | $13M |
| 2 |  NVAXNovavax, Inc. | 2 | 1 | $1.8B |
| 3 | JNJJohnson & Johnson | 1 | 1 | $621.2B |
| 4 |  BRNSBarinthus Biotherapeutics plc | 1 | — | $30M |
| 5 | MRNAModerna, Inc. | 1 | — | $98.1B |
| 6 | D DGXQuest Diagnostics Inc. | 1 | — | $26.4B |
| 7 |  CLNNClene Inc. | 1 | — | $49M |
| 8 | GNPXGenprex, Inc. | 1 | — | $2M |
| 9 | AZNAstraZeneca PLC | 1 | — | $261.2B |
| 10 |  NBTXNanobiotix S.A. | 1 | — | $1.3B |
About this data: Modality classification is derived from ClinicalTrials.gov sponsor descriptions and intervention metadata. Coverage is currently strongest in Small Molecule, Monoclonal Antibody, and Gene Therapy - finer-grain modalities (ADC, bispecific, CAR-T, oligonucleotide, peptide) are being added in upcoming releases. Companies with fewer than 10 upcoming trials in a modality are not ranked.